Gemcitabine/Cisplatin Combination Chemotherapy in Advanced non-Small Cell lung Cancer.
- Author:
Ho Sik SHIN
1
;
Dong Seung YOOK
;
Hee Kyoo KIM
;
Paul CHOI
;
Hyun Jeung LIM
;
Chan Bog PARK
;
Seung In HA
;
Chul Ho OK
;
Tae Won JANG
;
Maan Hong JUNG
Author Information
- Publication Type:Original Article
- Keywords: Non-small cell lung cancer; Gemcitabine; Cisplatin; Chemotherapy
- MeSH: Adenocarcinoma; Agranulocytosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung*; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy; Drug Therapy, Combination*; Female; Humans; Male; Survival Rate; Thrombocytopenia
- From:Tuberculosis and Respiratory Diseases 2003;55(1):98-106
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: To evaluate the efficacy and safety of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Forty patients (21 men, 19 women ; age range, 37 to 73 years; median, 63 years) with unresectable stage IIIB to IV NSCLC were evaluated. Patients received cisplatin 60mg/m2 (Day 1), gemcitabine 1200mg/m2 (Day 1 and 8) every 21 days. Eighteen patients had stage IIIB disease and 22 had stage IV. There were 28 patients of adenocarcinoma (70.0%), 11 of squamous cell carcinoma (27.5%), and one of large cell carcinoma (2.5%). RESULTS: Of 40 patients, no patients showed complete response while 15(37.5%) showed partial response, 7(17.5%) had stable diseases, 18(45%) had progressive diseases. During a total of 195 courses of chemotherapy, grade 3 or more granulocytopenia and thrombocytopenia occured in 12.5% and 2.5% of patients respectively. Non-hematologic toxicity was mild and easily controlled. There was one case of treatment-related death by pneumomia. The median survival was 55 weeks (95% CI, 34~75weeks), and the time to progression was 19 weeks (95% CI, 16~23weeks). One year survival rate was 55% and 2 year survival rate was 10%. CONCLUSION: The efficacy of cisplatin and gemcitabine combination chemotherapy was acceptable in the treatment of advanced NSCLC.
